Delving into the Latest Updates on Wuhan Pusheng Pharmacy Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

Enzymes	1

Primary objective: To investigate the safety of ursolic acid nanoliposomes for injection in patients with advanced hepatocellular carcinoma (HCC). Secondary objective: To preliminarily evaluate the clinical efficacy of ursolic acid nanoliposomes for injection in patients with advanced hepatocellular carcinoma (HCC).

Start Date04 May 2023

Sponsor / Collaborator

Wuhan Liyuanheng Pharmaceutical Technology Co., Ltd.

[+1]

100 Clinical Results associated with Wuhan Pusheng Pharmacy Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Wuhan Pusheng Pharmacy Co., Ltd.

Login to view more data

100 Deals associated with Wuhan Pusheng Pharmacy Co., Ltd.

Login to view more data

100 Translational Medicine associated with Wuhan Pusheng Pharmacy Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data